| Ytd | 88.68% | |
| 1y | 131.29% |
| Open | 78.33 | Prev Close | 78.15 | Low | 77.19 | High | 79.69 | Mkt Cap | 5.93B |
| Vol | 451.32K | Avg Vol | 759.24K | EPS | 0.90 | P/E | 86.48 | Forward P/E | 48.12 |
| Beta | 0.09 | Short Ratio | 5.35 | Inst. Own | 105.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-28 | 50-d Avg | 62.78 | 200-d Avg | 49.49 | 1yr Est | 98.00 |
LONDON, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA)
KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and ra
Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue mov
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight a
Canaccord Genuity analyst Edward Nash maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperf
Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and ra
Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular se
US stocks trade higher, Dow up 1% on Tuesday. Boeing gains 5% after reporting Q2 results. Kiniksa Ph
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet
Kiniksa Pharmaceuticals International NASDAQ: KNSA reported second-quarter ARCALYST revenue of $243.
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.3 per share
Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.30 per share which beat the
Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $930.000 million-$945.000 mil
- ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243. 6 million, representing ~55% year-over
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and ra
Despite a volatile market, AOUT, CMPR, NESR, CTO and KNSA are five stocks showing recent price stren
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pha
Let's take a look at four stocks, FLXS, ARKO, KNSA and BSET, with impressive net profit margins for
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Ove
Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice for investors looking to m
Does Kiniksa Pharmaceuticals International, plc (KNSA) have what it takes to be a top stock pick for
Kiniksa Pharmaceuticals International, plc (KNSA) was a big mover last session on higher-than-averag
Let's take a look at four stocks, BTSG, KNSA, ATI and VMI, with stellar net profit margins and risin
KNSA's Arcalyst sales continue to grow as raised 2026 revenue guidance and an expanding IL-1 pipelin
On June 22, 2026, Kiniksa Pharmaceuticals International PLC (KNSA) shares rose 3.5% today, bringing
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pha
TWFG, XPO, MUSA, FLYW and KNSA have been added to the Zacks Rank #1 (Strong Buy) List on June 18, 20
Kiniksa Pharmaceuticals International, plc (KNSA) might move higher on growing optimism about its ea
Companies Reporting Before The Bell • Unilever (NYSE:UL) is expected to report earnings for its fir
On Wednesday, 73 stocks hit new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings
Gainers
Stocks That Hit 52-Week Lows On Wednesday